Purpose: In Sturge-Weber disease, motor and cognitive defects are supposed to result mostly from severe epilepsy. They might, therefore be partly prevented by prophylactic antiepileptic drug treatment. This condition constitutes a possible model for the study of prophylactic drug treatment in severe epilepsy. In the present study, we compared the outcome of patients treated prospectively with phenobarbitone before the first seizure, with those referred following the first seizure, in order to identify the issues related to the evaluation of prophylactic treatment of severe epilepsy.
INTRODUCTION
Although the mechanisms of intractability of epilepsy remain poorly understood, there is growing evidence that it affects certain categories of patients from the very beginning of the first seizure disorder 1 . Prevention of the first seizure by prophylactic treatment could be one means of avoiding an intractable course, for conditions in which a high risk of intractability can be identified before the occurrence of the first seizure. However, such an unusual concept is likely to raise methodological difficulties that have not been addressed to date.
Sturge-Weber disease (SW) 2 is one of those rare conditions in which a high risk of intractable and devastating epilepsy can be predicted before the occurrence of any seizure. Indeed, it combines a facial port-wine stain over the area of the first branch of the trigeminal nerve (V 1 ) that can be identified from birth, and the ipsilateral leptomeninges that is responsible for the severe epilepsy that affects 80% of the children 3 . Choroid angiomas may also be observed. Epilepsy usually starts very early in life and often comprises prolonged convulsions as the initial manifestation, followed by frequent intractable and disabling seizures 4, 5 .
Mental retardation and motor deficits (that respectively affect 60% and 50% of patients) follow the onset of epilepsy [4] [5] [6] . Therefore, controlling epilepsy is a major aspect of treatment. Ideally, treatment should prevent the first seizures since they are likely to be devastating. In this perspective, Gilly et al., and Salman 6, 7 proposed treating 'before the onset of the seizures in the newborn with facial port wine stain' α associated pial angioma. They proposed to identify suitable cases on the basis of 'reduced cortical activity on EEG and/or abnormal cerebral scintography'.
From 1978, we applied this concept of prophylactic treatment prospectively in the Neuropaediatric Department of Saint Vincent de Paul Hospital, treating from birth all the patients with SW disease identified on the basis of a typical port-wine stain in the V 1 location. Since, at that date, phenobarbitone was the only anticonvulsant compound available for the neonatal period, this drug was selected for prophylactic treatment. The purpose of the present study was to compare the outcome of patients treated before the onset of seizures with those referred before 1978 and treated after the first seizure.
PATIENTS AND METHODS
We compared the 16 patients who, from 1978 to 1996, received phenobarbitone prospectively before any seizure to the 21 who had been referred to our department following first seizures, before 1978. All 37 children were born between 1969 and 1994 and had been referred to Saint-Vincent de Paul Hospital for SW disease. SW disease was suspected on the basis of the topography of the port-wine stain in the V 1 area, the presence of glaucoma and/or neurological manifestations, and confirmed by brain imaging, computed tomography scan (CT) and/or magnetic resonance imaging (MRI) 8 . We also included three children for whom a pial angioma was demonstrated on brain imaging although they had no facial angioma. Follow-up was at least 2 years.
For the whole series, we studied the characteristics of facial angioma, ocular manifestations, characteristics of the epilepsy, psycho-motor development, motor defects and the results of neuroimaging and neurophysiological investigations.
We then compared both groups, whether treated or not before the first seizures, in terms of characteristics of their epilepsy, occurrence of mental retardation, and of motor deficits. Regarding epilepsy, we considered age of onset, seizure characteristics, pharmacoresistance, occurrence of prolonged seizures lasting for more than 1 hour, and age at last seizure, or the age from which the child was having less than one seizure every other month. Pharmacoresistance was defined by the occurrence of more than one seizure a month with appropriate treatment. Age at seizure control was defined as that from which the child had less than one seizure every other month. For psychomotor development, children were considered as severely retarded when their intelligence quotient (IQ) was under 50, moderately delayed when IQ was between 50 and 80, and having normal development when IQ was over 80 or considered normal by the physician and those caring for the child at school. Motor deficit was graded as severe in the case of hemiplegia or hemiparesis with major muscle weakness, moderate in the case of inability to perform fine finger movements, and mild when there was discrete asymmetry between both sides or mild clumsiness in fine movements.
The same comparison between both groups was then performed according to the size of the angioma. On CT and/or MRI, we could distinguish extensive angiomas that affected more than one lobe or was bilateral, from localized angiomas that were restricted to one lobe.
RESULTS

Findings regarding the overall series
In the overall series combining both groups, there was a slight male predominance with 21 males to 16 females. Age at the end of follow-up ranged from 2 years 9 months to 28 years. There was no neonatal injury or family history of epilepsy or SW disease. All children but three had a facial port-wine stain in the area of V1. Other localization's could be associated (V2, V3, the limbs, trunk. . .) without any correlation between the size of the facial port-wine stain and the size of the pial angioma. All children had a pial angioma diagnosed on CT (atrophy, visualization of the angioma, calcifications, hypertrophy of the choroid plexus) and/or the MRI (atrophy, visualization of the angioma, accelerated myelination).
The angioma was small in 22 children and extensive in 15. Apart from the Klippel-Trenaunay syndrome in two children, there were no other abnormalities.
Epilepsy
Thirty two (85%) children had epilepsy. The mean age of onset of the seizures was 8 months (0.1 month-3 years). Only three (10%) children had their first seizure after the age of one year, and only one of them after the age of two.
Epilepsy was considered as severe in 18 patients (56.2%). Seventeen (53%) had at least one prolonged seizure. Eight of these 17 (47%) exhibited a motor deficit after the prolonged seizure. In addition, one patient had a prolonged seizure in the course of meningitis. The age of the first prolonged seizure was known for 14 children, and it initiated the seizure disorder for eight of them (57%). Occurrence of a prolonged seizure was associated with severe epilepsy in all cases except three. Of the 18 children with severe epilepsy, only four had never had a prolonged seizure. Therefore there was a significant relation between the occurrence of prolonged seizures and further severe epilepsy (P < 0.05).
The characteristics of the seizures were clearly identified for 28 children. They were generalized in three and partial in 25, of whom eight were complex partial, and three most often secondarily At the last visit, epilepsy remained uncontrolled for only five children, aged 5, 9, 10, 12 and 18 years. For eight other children, epilepsy had been stabilized, with therefore less than one seizure every other month, since the mean age of 6.1 years. Nineteen patients were completely seizure free from the mean age of 5.4 years. Surgery was performed in four patients and consisted of hemispherotomy in three, respectively at the ages of 3, 5 and 20 years, and all three became seizure free. One had had a callosotomy at the age of 11 that failed to totally control the seizures. Therefore, cessation of seizure occurred in the majority of the cases independently of surgery, and the risk of recurrent seizures seems to decrease strongly by the end of the first decade. 
Neurological outcome
The findings are summarized in Tables 1 and 2 . Twenty-three (63%) children suffered mental retardation, which was severe in nine (23%). The percentage of mental retardation was greatly increased by the occurrence of epilepsy, especially when the latter was severe.
Motor deficits affected 16 (48.6%) patients, it mostly mildly, but were more severe in patients with epilepsy.
Comparison between groups receiving or not prophylactic treatment
Epilepsy
The findings are shown in Table 3 . Five of the 16 children (31%) with prophylactic treatment remained free of seizures whereas there were none in the group without prophylactic treatment. Epilepsy started significantly later for children who received prophylactic treatment than for those who did not. There was a trend towards less severe epilepsy, with less prolonged seizures.
Psycho-motor development
Findings are shown in Table 4 : about half the patients exhibited less mental retardation in the population with prophylactic treatment than in that without. Severity of mental retardation tended to be milder in the group with prophylactic treatment.
Motor deficit
Findings are listed in Table 5 . The percentage of motor deficit was similar in both groups.
Findings according to the size of the angioma
The size of the angioma was evaluated based on leptomeningeal enhancement after Gadolinium R , atrophy and calcifications visible on CT scan or MRI (Table 6 ). Fifty percent of the children without prophylactic treatment had an extensive pial angioma compared to only 25% in the population treated before the onset of seizures. The findings show that 73% of the children with an extensive angioma had severe epilepsy compared to only 32% in the population with a localized angioma; 87% of the cases with extensive angioma were mentally retarded, severely for 60% of them, compared to only 45% with mental retardation and no case of severe mental retardation when the pial angioma was localized; likewise, motor deficit affected 80% of the children with extensive angioma, compared to only 27% when the pial angioma was small. There was no statistical difference within each subgroup by size of the angioma, regarding the incidence of epilepsy, mental retardation and motor deficit. However, there was a trend towards less severity of epilepsy and less mental retardation in the subgroups with prophylactic treatment.
DISCUSSION
The present study is the first to evaluate the impact of prophylactic antiepileptic drug treatment, in a selected paediatric population with high risk of severe, deleterious and refractory epilepsy. As with every first approach to a new concept, it faced methodological problems, which should be resolved in future studies. The most important was the absence of randomization of the two groups, which introduced both predictable and unpredictable bias. Although this study does not permit any definitive conclusion regarding the potential benefit of prophylactic antiepileptic drug treatment in SW disease, it provides arguments strong enough to convince patients and physicians of the necessity of a randomized study addressing this issue.
In the present series, the incidence of epilepsy was higher in the non-treated group (100%) than in those receiving prophylactic treatment (69%). In addition to any beneficial effect of treatment preventing the occurrence of epilepsy, two other reasons could account for this difference: (1) the fact that patients in the non-treated group had been referred for epilepsy but not those in the prophylactically treated group, (2) the fact that the size of the angioma was smaller in the non-treated group is another bias since the occurrence of seizures in SW disease is related to the size of the angioma 4, 9 . Nevertheless, 31% of the patients treated prophylactically did not develop seizures whereas this is the case in no more than 20% in non-selected series 3, 4, 6 .
In the present series, there was a contrast between motor function being similar in both groups, and cognitive function being clearly better in the prophylactically treated group. Motor and cognitive defects could result either from the seizures or from necrotic lesions due to the angioma [10] [11] [12] . Epilepsy has been shown to be a factor leading to worsening cerebral function in SW syndrome: indeed, regional cerebral blood flow (rCBF) measured in the area of the angioma using SPECT (single-photon emission computed tomography) is decreased after the first seizure, whereas it is increased before the occurrence of the first seizure 12, 13 . It may appear paradoxical to have a protective effect on cognitive functions from a compound (phenobarbitone) known to affect cognitive function when given in early life, particularly in brain damaged individuals. We take this as an argument that the benefit of protection against epilepsy outweighed the negative impact of the compound on developing cognitive function. Lack of protective effect of anticonvulsant treatment on motor function suggests that ischaemic phenomena are mostly responsible for the motor defects in SW disease. Indeed, the disease proves to be progressive from very early in life, before the age range of the development of cognitive functions, and independently from epilepsy; rCBF decreases within the first months of life, whether the patient has experienced seizures or not 13 . Therefore, it seems likely that motor functions are affected by ischaemic events related to the size of the angioma, whereas the cognitive impact is more likely linked to epilepsy. Although no conclusion can be drawn regarding the absolute benefit of prophylactic treatment in patients with SW disease, better epileptic and cognitive outcome in treated patients suggests that the hypothesis of a benefit of prophylactic treatment is worth being pursued, but that a prospective randomized study is required to establish this benefit. Such a prospective study should take in account the size of the angioma, and include in endpoints, not only the occurrence and severity of the epilepsy, but also the impact on both cognitive and motor function. New techniques of imaging (MRI with Gadolinium R and SPECT) may be helpful for an early diagnosis of the pial angioma and for the choice of the children who could be included.
Another difficult problem is the choice of the appropriate medication. For this study, phenobarbitone had been chosen because it was the only compound available for the treatment of epilepsy in the newborn and in infancy at the time the study was designed. As a prophylaxis, the drug should have the same requirements as for therapy: high efficacy, low toxicity and good bioavailability, taking in account the young age of the patients'. Phenobarbitone has been shown to interfere with the development of cognitive function 14 and animal studies have shown this negative impact to be even higher in cases with brain lesions 15 . However, prophylactic use of phenobarbitone was associated with a better outcome than no prophylactic treatment in the present study. Carbamazepine could be exhibited, but bioavailability is unpredictable with this compound in the newborn period, when protection is particularly important 16 , and several cases of infantile spasms being triggered by this compound, when given in early infancy, are on record [17] [18] [19] . Phenytoin has prove ineffective and difficult to administer in infancy, given its non-linear pharmacokinetics 20 . Benzodiazepines could be used, but the inefficacy is likely to be transient and the ineffect on cognitive function would clearly be a major concern. Vigabatrin is particularly effective in infantile epilepsy 21 but the issue of its causation of visual field defect remains to be clarified, especially for a disease that commonly affects visual fields 22 . Valproate could be a candidate, although the effect in symptomatic partial epilepsy seems to be moderate compared to that of carbamazepine 23 .
CONCLUSIONS
Prophylactic treatment of epilepsy is a matter of growing interest. This study shows that, even in a highly selected group of patients with a high risk of severe epilepsy, the benefits of prophylactic treatment may be very difficult to demonstrate, and in SW would need a number of patients randomized after imaging had demonstrated the angioma and determined its
